<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Soukup J</submitter><funding>Ministerstvo Zdravotnictví Ceské Republiky</funding><pagination>2484-2492</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7933931</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>25(5)</volume><pubmed_abstract>In somatotroph pituitary tumours, somatostatin analogue (SSA) therapy outcomes vary throughout the studies. We performed an analysis of cohort of patients with acromegaly from the Czech registry to identify new prognostic and predictive factors. Clinical data of patients were collected, and complex immunohistochemical assessment of tumour samples was performed (SSTR1-5, dopamine D2 receptor, E-cadherin, AIP). The study included 110 patients. In 31, SSA treatment outcome was evaluated. Sparsely granulated tumours (SGST) differed from the other subtypes in expression of SSTR2A, SSTR3, SSTR5 and E-cadherin and occurred more often in young. No other clinical differences were observed. Trouillas grading system showed association with age, tumour size and SSTR2A expression. Factors significantly</pubmed_abstract><journal>Journal of cellular and molecular medicine</journal><pubmed_title>Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly.</pubmed_title><pmcid>PMC7933931</pmcid><funding_grant_id>NV19‐01‐00435</funding_grant_id><funding_grant_id>NV19-01-00435</funding_grant_id><pubmed_authors>Krsek M</pubmed_authors><pubmed_authors>Soukup J</pubmed_authors><pubmed_authors>Cap J</pubmed_authors><pubmed_authors>Gabalec F</pubmed_authors><pubmed_authors>Skarkova V</pubmed_authors><pubmed_authors>Ryska A</pubmed_authors><pubmed_authors>Popovska L</pubmed_authors><pubmed_authors>Olsovska V</pubmed_authors><pubmed_authors>Hana V</pubmed_authors><pubmed_authors>Vanuga P</pubmed_authors><pubmed_authors>Michalova K</pubmed_authors><pubmed_authors>Dvorakova E</pubmed_authors><pubmed_authors>Stary K</pubmed_authors><pubmed_authors>Manethova M</pubmed_authors><pubmed_authors>Cesak T</pubmed_authors><pubmed_authors>Michnova L</pubmed_authors><pubmed_authors>Netuka D</pubmed_authors><pubmed_authors>Hornychova H</pubmed_authors><pubmed_authors>Krcma M</pubmed_authors><pubmed_authors>Lazurova I</pubmed_authors></additional><is_claimable>false</is_claimable><name>Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly.</name><description>In somatotroph pituitary tumours, somatostatin analogue (SSA) therapy outcomes vary throughout the studies. We performed an analysis of cohort of patients with acromegaly from the Czech registry to identify new prognostic and predictive factors. Clinical data of patients were collected, and complex immunohistochemical assessment of tumour samples was performed (SSTR1-5, dopamine D2 receptor, E-cadherin, AIP). The study included 110 patients. In 31, SSA treatment outcome was evaluated. Sparsely granulated tumours (SGST) differed from the other subtypes in expression of SSTR2A, SSTR3, SSTR5 and E-cadherin and occurred more often in young. No other clinical differences were observed. Trouillas grading system showed association with age, tumour size and SSTR2A expression. Factors significantly</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Mar</publication><modification>2025-04-05T13:48:29.112Z</modification><creation>2021-03-18T08:36:14Z</creation></dates><accession>S-EPMC7933931</accession><cross_references><pubmed>33491286</pubmed><doi>10.1111/jcmm.16173</doi></cross_references></HashMap>